MOUNT SINAI LIVER CANCER PROGRAM. 17th ANNIVERSARY. “LIVER CANCER: UPDATED REVIEW OF CLINICAL MANAGEMENT AND TRANSLATIONAL SCIENCE”

Friday, December 16, 2022, 8:30 AM - 4:30 PM, Leon & Norma Hess Center for Science and Medicine, Davis Auditorium, 1470 Madison Avenue, New York, NY


There has been a revolution in the landscape of therapies for liver cancer, both in hepatocellular carcinoma (HCC) and in cholangiocarcinoma (CCA). Targeted physicians are not aware of the impact of new therapies in HCC and CCA in the clinical practice. There is a need to educated clinicians on the landcape of therapies available and the sequencing to be used. In addition, they should be educated on the cutting-edge research in liver cancer, particularly regarding new insights in the pathogenesis of the disease and new molecular and immune therapies. The program aims to both increase the knowledge and competence of the attendees along with improving the scientific insight on the understanding of the molecular basis of these lethal diseases based on recent discoveries. The meeting is intended to provide a summary of advances in science and clinical management of liver cancer, including the research conducted in Mount Sinai.

1. Review the molecular pathogenesis and target for therapies in HCC and CCA.
2. Review the current role of surgical and loco-regional treatments for liver cancer.
3. Critical analysis of molecular and immunotherapies in the management of advanced HCC
4. Assess cutting edge science conducted at the Mt Sinai Liver Cancer Program-2022

Registration Fee: $25.00

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (6.50 hours)

Discounted sleeping rooms can be reserved with our Housing Manager, Denise Newman, Cell/Text: 347-236-7181 Phone:718-835-4911; email: [email protected]

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

Icahn School of Medicine at Mount Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Friday, December 16, 2022

We gratefully acknowledge the support of the following who have made this activity possible:

Exelixis, Eisai, AstraZeneca, Glycotest

Exelixis, Eisai, AstraZeneca, Glycotest